NCT00307034 - Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule | Biotech Hunter

Enrollment

351

Participants

Timeline

Start Date

January 1, 2006

Primary Completion Date

January 1, 2007

Study Completion Date

January 25, 2007

Conditions

Infections, Streptococcal

Interventions

BIOLOGICAL

GSK Biologicals' 10-valent pneumococcal conjugate vaccine.

Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).

BIOLOGICAL

Infanrix hexa.

Intramuscular injection, 3 doses (2-4-11 months of age schedule).

BIOLOGICAL

Infanrix-IPV/Hib.

Intramuscular injection, 3 doses (2-4-11 months of age schedule).

Trial Locations (8)

GSK Investigational Site, Hvidovre

GSK Investigational Site, Morvik

GSK Investigational Site, Oslo

GSK Investigational Site, Dolný Kubín

GSK Investigational Site, Ružomberok

GSK Investigational Site, Gothenburg

GSK Investigational Site, Örebro

GSK Investigational Site, Umeå